Update shared on 18 Nov 2025
Fair value Decreased 7.71%Analysts have revised their price target for Akums Drugs and Pharmaceuticals downward from ₹691.67 to ₹638.33, citing updated assessments of growth prospects and market conditions.
What's in the News
- A board meeting is scheduled for November 13, 2025, at 14:30 IST to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).
- Dr. Shantanu Rajaram Chobhe has been designated as Senior Management Personnel in the role of President (CQA) Formulation, effective November 13, 2025 (Key Developments).
- Mr. Vinayak Bhat has been designated as Senior Management Personnel in the position of VP (Operations) API division, effective November 13, 2025 (Key Developments).
- Approval has been granted to invest USD 24 million in Akums Healthcare (Zambia) Private Limited, a subsidiary located in the Republic of Zambia (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from ₹691.67 to ₹638.33.
- Discount Rate has risen slightly, moving from 13.34% to 14.02%.
- Revenue Growth projection has increased marginally, from 11.65% to 12.08%.
- Net Profit Margin expectation has improved, rising from 8.25% to 8.55%.
- Future P/E ratio has declined from 34.87x to 29.46x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.